Recently, Beilu Pharmaceutical (300016) released the "2025 First Quarter Report". Building on the stable growth in annual performance in 2024, Beilu Pharmaceutical has had a great start in 2...
Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regula...
Recently, Hichi Pharmaceutical's iopamidol API received the "Approval Notice for the Marketing Application of Chemical APIs" from the National Medical Products Administration. This is an...
Recently, Zhejiang Hichi Pharmaceutical Corporation Limited, a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received the product registration certificate for Iodixanol API issued by the Korea...
Recently, Beijing Beilu Pharmaceutical Co., Ltd. and Anhui Chengqing Tang Traditional Chinese Medicine Co., Ltd. formally signed a strategic cooperation agreement in Bozhou, Anhui. The two parties wil...
On December 12, 2024, Beilu Pharmaceutical participated in the bidding process for the 10th National Drug Centralized Procurement organized by the National Joint Drug Procurement Office. Beilu Pharmac...